TARGETED THERAPY FOR METASTATIC RENAL CELL CANCER

2010 ◽  
Vol 65 (2) ◽  
pp. 115-121
Author(s):  
C. Verbaeys ◽  
P. Hoebeke ◽  
S. Van Belle ◽  
S. Rottey
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 519-519
Author(s):  
Mustafa Erman ◽  
Zafer Arik ◽  
Saadettin Kilickap ◽  
Cenk Yucel Bilen ◽  
Sertac Yazici ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Indirect Evidence ◽  
Cancer Center ◽  
Interferon Α ◽  
Targeted Agents ◽  
Metastatic Renal Cell Cancer ◽  
The Impact

519 Background: Though targeted agents have dramatically changed the outcome of metastatic renal cell cancer (mRCC) patients, it has not been possible to show any survival advantage, probably due to substantial cross-over in randomized trials. The change in survival times following the introduction of targeted agents may yield indirect evidence of an improvement in overall survival (OS). Methods: First targeted agents were available in Turkey in 2007. Data from the hospital charts of adult mRCC patients treated between January 2003 and December 2012 were included. Demographic and clinical findings along with patient, tumor, and treatment-related prognostic factors and their correlation with progression-free survival (PFS), and OS were analyzed. Results: One hundred and seventy six patients had metastatic disease. Of these, 107 patients received at least one dose of interferon-α and 74 patients received at least one targeted therapy. Median follow-up was 19.1 months (range 1-97 months) and median OS was 24.6 months (95% CI, 20.4-28.9). Median OS of patients who received any targeted therapy was significantly better than those who did not (29.1 mths [95% CI, 21.4-36.8] vs 19.4 mths [95% CI, 14.2-24.6]; p=0.036). The study period of 2003-2012 was subdivided into 4 consecutive groups. Although not statistically significant, a trend toward better survival was observed with advancing years and increasing targeted therapy use (p=0.09). For example, median OS of patients diagnosed in 2006 and 2007 was 14.1 months (95% CI, 10.4-17.8) while median OS of those diagnosed in 2010 or later was 30.8 months (95% CI, 18.3-43.3). Patients in intermediate and poor Memorial Sloan-Kettering Cancer Center risk groups benefited more from targeted therapies (p=0.001). Conclusions: Patients who received any targeted therapy lived longer than those who did not. Trend toward better survival was associated with advancing years and increasing targeted therapy use. The introduction of targeted agents appear to benefit mRCC patients in terms of OS as well.

Long survival (SV) for metastatic renal cell cancer (mRCC) after cytoreductive nephrectomy (CN) plus lung metastasectomy (LM) without targeted therapy (TT).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e16564-e16564
Author(s):  
Jose F. Corona-Cruz ◽  
Miguel Patricio Moscoso-Fernandez Salvador ◽  
Laura Alejandra Ramirez-Tirado ◽  
Josue Andres Gonzalez-Luna ◽  
Miguel A. Alvarez ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cytoreductive Nephrectomy ◽  
Long Survival ◽  
Metastatic Renal Cell Cancer ◽  
Lung Metastasectomy

scholarly journals Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer

2017 ◽  
Vol 7 (4) ◽  
pp. 591-594 ◽  
Author(s):  
Senji Hoshi ◽  
Kenji Numahata ◽  
Hidenori Kanno ◽  
Masahiko Sato ◽  
Akihito Kuromoto ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Molecular Targeted Therapy ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

scholarly journals Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated with Targeted Therapies

2016 ◽  
Vol 3 (1) ◽  
pp. 12-22 ◽  
Author(s):  
Steven M Yip ◽  
Daniel Y. C. Heng ◽  
Patricia A. Tang
Keyword(s):  
Overall Survival ◽  
Body Composition ◽  
Targeted Therapy ◽  
Clinical Outcomes ◽  
Renal Cell Cancer ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer ◽  
The Impact

Treatment of metastatic renal cell cancer (mRCC) currently focuses on inhibition of the vascular endothelial growth factor pathway and the mammalian target of rapamycin (mTOR) pathway. Obesity confers a higher risk of RCC. However, the influence of obesity on clinical outcomes in mRCC in the era of targeted therapy is less clear. This review focuses on the impact of body composition on targeted therapy outcomes in mRCC. The International Metastatic Renal Cell Carcinoma Database Consortium database has the largest series of patients evaluating the impact of body mass index (BMI) on outcomes in mRCC patients treated with targeted therapy. Overall survival was significantly improved in overweight patients (BMI ? 25 kg/m2), and this observation was externally validated in patients who participated in Pfizer trials. In contrast, sarcopenia is consistently associated with increased toxicity to inhibitors of angiogenesis and mTOR. Strengthening patients with mRCC and sarcopenia, through a structured exercise program and dietary intervention, may improve outcomes in mRCC treated with targeted therapies. At the same time, the paradox of obesity being a risk factor for RCC while offering a better overall survival in response to targeted therapy needs to be further evaluated.

scholarly journals Sequential Targeted Therapy Following Pazopanib (PZ) in Patients (PTS) with Metastatic Renal Cell Cancer (MRCC): Efficacy and Toxicity

2012 ◽  
Vol 23 ◽  
pp. ix278
Author(s):  
F. Pons Valladares ◽  
T.K. Choueiri ◽  
T.E. Hutson ◽  
T.B. Powles ◽  
C. Porta ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity

2014 ◽  
Vol 12 (4) ◽  
pp. 262-269 ◽  
Author(s):  
Joaquim Bellmunt ◽  
Francesc Pons ◽  
Abigail Foreshew ◽  
André P. Fay ◽  
Thomas Powles ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

Nephrotoxicity induced by VEGF-target agents in patients with metastatic renal cell cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 432-432
Author(s):  
Tomoyuki Kato ◽  
Shoko Nakayama ◽  
Takafumi Narisawa ◽  
Atsushi Yamagishi ◽  
Toshihiko Sakurai ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Adverse Events ◽  
Serum Creatinine ◽  
Serum Creatinine Level ◽  
Creatinine Level ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Target Therapy ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

432 Background: A study was undertaken to investigate the association between treatment with vascular endothelial growth factor (VEGF)-targeted therapy for metastatic renal cell cancer (mRCC) and nephrotoxicity. Methods: Retrospective data were collected for mRCC patients received VEGF-targeted therapy between January 2005 and December 2010. We investigated renal adverse events and clinically significant increased serum creatinine level in patients who received VEGF target therapy. GFR was estimated with the Modification of Diet in Renal Disease (MDRD) formula. Results: Ninety one patients with mRCC who received sunitinib (n=46), sorafenib (n=38), axitnib (n=9) were included in this analysis. As for renal adverse events, acute renal failure occurred in 1 (2.2%) of 46 sunitinib recipients. Facial edema occurred 17 (37.0%) in sunitinib recipients, 2 (5.3%) of sorafenib recipients, 2 (22.2%) of axitinib recipients. In sunitinib recipients, all of these adverse events observed in ‘off’ period. During administration, gradual and significant increase of serum creatinine was observed in sunitinib recipients compared for sorafenib or axitinib recipients (p= 0.04). Significant decrease of GFR compared for baseline correlated with increase of serum creatinine level developed in ‘on’ period of 6 sunitinib administration cycle (p=0.013), but returned to baseline level after 2weeks cessation. No significant change was observed in serum creatinine level and GFR in patients received other VEGF-target agents. Conclusions: Our data suggest that nephrotoxicity developed in a high percentage of patients on sunitinib compared for sorafenib and axitinib in mRCC patients. Clinicians should observe renal function of sunitinib recipients more carefully in ‘off’ period as well as ‘on’ period.

Sign in / Sign up

Export Citation Format

Share Document